Study of daratumumab, bortezomib, and dexamethasone for plasmablastic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have plasmablastic lymphoma confirmed by biopsy, and the tumor must be CD38-positive (at least 5% of cells).
- Your lymphoma is relapsed or refractory after at least one standard chemotherapy treatment (with certain transplant situations allowed).
- You are at least 18 years old, and your daily functioning is not too limited (ECOG 0–3).
- You have at least one tumor area seen on scans that is big enough to measure.
- If you have HIV, it must be controlled with your current anti-HIV medicines (cART).
- If you can become pregnant (or you’re a man sexually active with a pregnancy-capable partner), you must use effective birth control for the required time after study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
This trial tests a new drug called elranatamab in patients with plasmablastic lymphoma (a rare blood cancer) who have already completed their first treatment. The drug may help prevent the cancer from coming back or growing, and the trial includes patients with and without HIV.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
This Phase 2 study tests whether adding daratumumab to standard chemotherapy, followed by a stem cell transplant, can improve outcomes in primary plasma cell leukemia. It aims to see how well this treatment works and whether it’s safe for people who are eligible for intensive therapy and transplant.
This trial tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia (pPCL). It uses two different drug combinations that include daratumumab, given one after the other, followed by maintenance daratumumab. The goal is to see if this approach is safe and works well.
This trial tests a new drug called teclistamab for people with plasmablastic lymphoma that has come back or not responded to standard treatments. The goal is to see if teclistamab can shrink tumors and control the disease.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.